Equities research analysts expect that Advaxis, Inc. (NASDAQ:ADXS) will report $3.03 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Advaxis’ earnings, with estimates ranging from $3.00 million to $3.05 million. Advaxis posted sales of $3.79 million in the same quarter last year, which would indicate a negative year over year growth rate of 20.1%. The business is scheduled to report its next earnings results on Friday, March 9th.

On average, analysts expect that Advaxis will report full year sales of $3.03 million for the current year, with estimates ranging from $12.21 million to $13.00 million. For the next financial year, analysts expect that the business will post sales of $12.68 million per share, with estimates ranging from $12.27 million to $13.10 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Advaxis.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). The company had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%.

ADXS has been the topic of a number of research analyst reports. HC Wainwright set a $23.00 price objective on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 price objective on shares of Advaxis and gave the company a “buy” rating in a research report on Thursday, December 28th.

Several hedge funds have recently made changes to their positions in ADXS. Bank of Montreal Can boosted its holdings in shares of Advaxis by 16,465.9% during the 4th quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares in the last quarter. Nexthera Capital LP boosted its holdings in shares of Advaxis by 160.3% during the 2nd quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock valued at $1,635,000 after buying an additional 155,200 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Advaxis by 7.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock valued at $11,572,000 after buying an additional 119,980 shares in the last quarter. OxFORD Asset Management LLP bought a new stake in shares of Advaxis during the 2nd quarter valued at $498,000. Finally, DAFNA Capital Management LLC boosted its holdings in shares of Advaxis by 43.6% during the 2nd quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock valued at $1,603,000 after buying an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 42.96% of the company’s stock.

Shares of Advaxis (NASDAQ ADXS) traded down $0.03 during trading on Thursday, reaching $2.93. 657,209 shares of the company’s stock were exchanged, compared to its average volume of 1,020,000. The stock has a market cap of $120.32, a P/E ratio of -1.27 and a beta of 1.91. Advaxis has a fifty-two week low of $2.71 and a fifty-two week high of $10.06.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/02/zacks-brokerages-expect-advaxis-inc-adxs-will-announce-quarterly-sales-of-3-03-million.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.